Vytrus Biotech S.A. (VYT) - Total Liabilities
Based on the latest financial reports, Vytrus Biotech S.A. (VYT) has total liabilities worth €4.35 Million EUR (≈ $5.09 Million USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check VYT cash and liquid asset ratio to evaluate the company's liquid asset resilience ratio.
Vytrus Biotech S.A. - Total Liabilities Trend (2020–2025)
This chart illustrates how Vytrus Biotech S.A.'s total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see balance sheet size of Vytrus Biotech S.A..
Vytrus Biotech S.A. Competitors by Total Liabilities
The table below lists competitors of Vytrus Biotech S.A. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Origin Property PCL
BK:ORI
|
Thailand | ฿42.79 Billion |
|
YESASIA HOLDINGS LTD
F:4CM
|
Germany | €83.70 Million |
|
Nynomic AG
F:M7U
|
Germany | €32.87 Million |
|
AYER Holdings Bhd
KLSE:2305
|
Malaysia | RM104.27 Million |
|
Amulaire Thermal Technology
TW:2241
|
Taiwan | NT$856.52 Million |
|
Securitag Assembly Group Co Ltd
TWO:6417
|
Taiwan | NT$1.21 Billion |
|
NH SPAC 2
KQ:206640
|
Korea | ₩37.46 Billion |
|
MEDIFAST INC
NYSE:MED
|
USA | $64.02 Million |
Liability Composition Analysis (2020–2025)
This chart breaks down Vytrus Biotech S.A.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See Vytrus Biotech S.A. (VYT) net asset quality to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 3.03 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.42 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.30 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Vytrus Biotech S.A.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Vytrus Biotech S.A. (2020–2025)
The table below shows the annual total liabilities of Vytrus Biotech S.A. from 2020 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | €4.35 Million ≈ $5.09 Million |
+13.44% |
| 2024-12-31 | €3.84 Million ≈ $4.49 Million |
-4.57% |
| 2023-12-31 | €4.02 Million ≈ $4.70 Million |
+23.76% |
| 2022-12-31 | €3.25 Million ≈ $3.80 Million |
+10.85% |
| 2021-12-31 | €2.93 Million ≈ $3.43 Million |
+12.83% |
| 2020-12-31 | €2.60 Million ≈ $3.04 Million |
-- |
About Vytrus Biotech S.A.
Vytrus Biotech, S.A. develops, produces, and sells active ingredients from plant stem cells in Spain and internationally. It offers Clarivine that activates skin's regeneration processes; Quora Noni biomics for rejuvenating the skin microbiota; Deobiome Noni, a prebiotic deodorant to reduce the generation of body odour; Sarcoslim Re-Shape, an active ingredient to reduce fat on tissue; Capilia Lon… Read more